Literature DB >> 18095276

Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers.

Daniela Eser1, Gregor Leicht, Jürgen Lutz, Stephan Wenninger, Valerie Kirsch, Cornelius Schüle, Susanne Karch, Thomas Baghai, Oliver Pogarell, Christine Born, Rainer Rupprecht, Christoph Mulert.   

Abstract

Experimental panic induction with cholecystokinin tetrapeptide (CCK-4) is considered as a suitable model to investigate the pathophysiology of panic attacks. While only a few studies investigated the brain activation patterns following CCK-4, no data are available on the putative involvement of the amygdala in the CCK-4 elicited anxiety response. We studied the functional correlates of CCK-4-induced anxiety in healthy volunteers by means of functional magnetic resonance imaging (fMRI) and region of interest (ROI) analysis of the amygdala. Sixteen healthy volunteers underwent challenge with CCK-4 compared with placebo in a single-blind design. Functional brain activation patterns were determined for the CCK-4-challenge, the placebo response and anticipatory anxiety (AA). CCK-4-induced anxiety was accompanied by a strong and robust activation (random effects analysis, P < 0.00001, uncorrected for multiple testing) in the ventral anterior cingulate cortex (ACC), middle and superior frontal gyrus, precuneus, middle and superior temporal gyrus, occipital lobe, sublobar areas, cerebellum, and brainstem. In contrast, random effects group analysis for placebo and AA using the same level of significance generated no significant results. Using a more liberal level of significance, activations could be observed in some brain regions such as the dorsal part of the ACC during AA (random effects analysis, P < 0.005). Overall functional responses did not differ between panickers and nonpanickers. Only 5 of 11 subjects showed strong amygdala activation. However, ROI analysis pointed towards higher scores in fear items in these subjects. In conclusion, while overall brain activation patterns are not related to the subjective anxiety response to CCK-4, amygdala activation may be involved in the subjective perception of CCK-4-induced fear.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18095276      PMCID: PMC6870703          DOI: 10.1002/hbm.20522

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  58 in total

1.  Cognitive and emotional influences in anterior cingulate cortex.

Authors: 
Journal:  Trends Cogn Sci       Date:  2000-06       Impact factor: 20.229

2.  CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects.

Authors:  R B Lydiard; J C Ballenger; M T Laraia; M D Fossey; M C Beinfeld
Journal:  Am J Psychiatry       Date:  1992-05       Impact factor: 18.112

3.  Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge.

Authors:  P J Whalen; S L Rauch; N L Etcoff; S C McInerney; M B Lee; M A Jenike
Journal:  J Neurosci       Date:  1998-01-01       Impact factor: 6.167

Review 4.  Functional neuroimaging studies in posttraumatic stress disorder.

Authors:  S L Rauch; L M Shin
Journal:  Ann N Y Acad Sci       Date:  1997-06-21       Impact factor: 5.691

5.  Cerebral glucose metabolism associated with a fear network in panic disorder.

Authors:  Yojiro Sakai; Hiroaki Kumano; Masami Nishikawa; Yuji Sakano; Hisanobu Kaiya; Etsuko Imabayashi; Takashi Ohnishi; Hiroshi Matsuda; Asako Yasuda; Atsushi Sato; Mirko Diksic; Tomifusa Kuboki
Journal:  Neuroreport       Date:  2005-06-21       Impact factor: 1.837

6.  Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.

Authors:  J Shlik; A Aluoja; V Vasar; E Vasar; T Podar; J Bradwejn
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

7.  Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.

Authors:  H J van Megen; H G Westenberg; J A den Boer; B Slaap; A Scheepmakers
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

8.  Brain systems mediating aversive conditioning: an event-related fMRI study.

Authors:  C Büchel; J Morris; R J Dolan; K J Friston
Journal:  Neuron       Date:  1998-05       Impact factor: 17.173

9.  A functional MRI study of human amygdala responses to facial expressions of fear versus anger.

Authors:  P J Whalen; L M Shin; S C McInerney; H Fischer; C I Wright; S L Rauch
Journal:  Emotion       Date:  2001-03

10.  Lymphocyte cholecystokinin concentrations in panic disorder.

Authors:  F Brambilla; L Bellodi; G Perna; A Garberi; A Panerai; P Sacerdote
Journal:  Am J Psychiatry       Date:  1993-07       Impact factor: 18.112

View more
  23 in total

Review 1.  Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences.

Authors:  Christian Grillon; Oliver J Robinson; Brian Cornwell; Monique Ernst
Journal:  Neuropsychopharmacology       Date:  2019-06-21       Impact factor: 7.853

2.  Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications.

Authors:  Carey D Balaban; Rolf G Jacob; Joseph M Furman
Journal:  Expert Rev Neurother       Date:  2011-03       Impact factor: 4.618

Review 3.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

4.  Neural correlates of spontaneous panic attacks.

Authors:  Thomas Dresler; Tim Hahn; Michael M Plichta; Lena H Ernst; Sara V Tupak; Ann-Christine Ehlis; Bodo Warrings; Jürgen Deckert; Andreas J Fallgatter
Journal:  J Neural Transm (Vienna)       Date:  2011-01-04       Impact factor: 3.575

Review 5.  A way forward for anxiolytic drug development: Testing candidate anxiolytics with anxiety-potentiated startle in healthy humans.

Authors:  Christian Grillon; Monique Ernst
Journal:  Neurosci Biobehav Rev       Date:  2020-10-07       Impact factor: 8.989

6.  Structural evidence for involvement of a left amygdala-orbitofrontal network in subclinical anxiety.

Authors:  Karen Blackmon; William B Barr; Chad Carlson; Orrin Devinsky; Jonathan DuBois; Daniel Pogash; Brian T Quinn; Ruben Kuzniecky; Eric Halgren; Thomas Thesen
Journal:  Psychiatry Res       Date:  2011-07-30       Impact factor: 3.222

7.  Functional t1ρ imaging in panic disorder.

Authors:  Vincent A Magnotta; Casey P Johnson; Robin Follmer; John A Wemmie
Journal:  Biol Psychiatry       Date:  2013-10-21       Impact factor: 13.382

Review 8.  The neurocircuitry of fear, stress, and anxiety disorders.

Authors:  Lisa M Shin; Israel Liberzon
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

9.  Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects.

Authors:  Peter Zwanzger; Maxim Zavorotnyy; Elena Gencheva; Julia Diemer; Harald Kugel; Walter Heindel; Tillmann Ruland; Patricia Ohrmann; Volker Arolt; Katharina Domschke; Bettina Pfleiderer
Journal:  Neuropsychopharmacology       Date:  2013-03-05       Impact factor: 7.853

10.  Unstable prefrontal response to emotional conflict and activation of lower limbic structures and brainstem in remitted panic disorder.

Authors:  Natalya Chechko; Renate Wehrle; Angelika Erhardt; Florian Holsboer; Michael Czisch; Philipp G Sämann
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.